Vitestro, a Netherlands-based developer of autonomous robotic phlebotomy devices, has raised $70M in an oversubscribed Series B funding round backed by Labcorp Venture Fund, Mayo Clinic, Sutter Health, and others including Invest-NL, EIC Fund, Sonder Capital, and NYBC Ventures. The company builds Aletta, the world's first fully autonomous robotic device for blood collection that handles everything from tourniquet to bandaging using AI, NIR, ultrasound, and Doppler imaging. The capital will accelerate commercial rollout in Europe following CE marking and prepare for US market entry.
Robotic Phlebotomy Surges Amid Labor Crunch
Vitestro's raise follows its CE mark in August 2024 and early orders like Odense University Hospital's pre-order of three devices and Result Laboratorium's two. Precihealth, a Swiss rival, announced a strategic investment from Intermountain Health in August 2025 for US trials. The timing aligns with post-COVID phlebotomy staffing shortages pushing hospitals toward automation, where one supervisor can oversee up to three Aletta devices.
Manual Errors Plague 60-70% of Lab Tests
Preanalytical errors from manual blood draws account for 60-70% of lab issues, driven by global phlebotomist shortages including 18,400 annual US openings. High patient volumes and turnover exacerbate inconsistent vein access and sample quality. Current solutions rely on skilled labor facing burnout, failing to standardize processes or enable 24/7 operations.
Aletta Achieves 95% First-Stick Success
Aletta uses multimodal imaging for sub-millimeter vein precision, delivering 95% first-stick success and 98% patient acceptance in the ADOPT trial, with 85% reporting less or similar pain. Unlike semi-autonomous rivals like Veebot that require human oversight, Aletta fully automates the workflow. BHealthCare's HEIVA offers similar autonomy but lacks CE marking and deployments.
AI Vein Mapping Outpaces Competitors
Vitestro's device integrates into lab workflows, addressing hard-to-puncture patients where traditional methods fail. Trial results at WorldLab 2024 highlighted its edge over manual phlebotomy.
As Toon Overbeeke, CEO noted:
"To close this financing reflects strong conviction in our mission to set a new standard in autonomous diagnostic blood collection."
Strategic Investors Signal US Ambitions
New backers like Labcorp Venture Fund and Mayo Clinic join prior investors Sonder Capital with robotics exits like Auris Health to J&J, and NYBC Ventures focused on blood tech. Invest-NL committed €20M for Dutch scale-ups, while EIC Fund provides EU deeptech support. This mix signals validation for Vitestro's path from EU commercialization to US FDA clearance.
Blood Robot Market Grows to $2.87B
The blood collection robot market stands at $400M in 2023, projected to reach $2.87B by 2033 at 22.4% CAGR. Broader blood collection devices hit $10.11B TAM by 2026 with 7.53% CAGR to 2034. Trends like AI vein imaging and automation combat staffing crises fueling capital into the space.
Health Systems Eye Global Standardization
Vitestro leads with real deployments versus unfunded Veebot ($70K angel) or early-stage BHealthCare. Precihealth's undisclosed strategic funding underscores the US race, but Vitestro's CE-marked Aletta and hospital pilots position it ahead.
Ex-BD Leader Drives Engineering Scale
Co-founder Brian Joseph scaled Zarafa to an Amazon acquisition in 2013, while VP Engineering Bas Nieuwenhuis led R&D at BD Kiestra lab automation before its BD buyout. CTO Bert Wiggers brings 25 years in electro-mechanical R&D. This team complements CEO Toon Overbeeke's vision born from personal blood draw frustrations.
EU Rollout Funds US Clinical Push
With Amsterdam UMC set to deploy Aletta by 2027 and Northwestern Medicine multi-year trials underway, the funding supports field service hiring, engineering scale, and US partnerships with Mayo Clinic and Baylor Scott & White.